ReviewMemorias do Instituto Oswaldo Cruz2011
Platform for Plasmodium vivax vaccine discovery and development.
Review in Memorias do Instituto Oswaldo Cruz, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Profiling the antibody response of humans protected by immunization with Plasmodium vivax radiation-attenuated sporozoites.Scientific reports · 2024Article
- Review
- Liver Function Test Abnormalities in Experimental and ClinicalThe American journal of tropical medicine and hygiene · 2020Article
- On the Evolution and Function ofFrontiers in genetics · 2018Article
- Article
- Host Cell Tropism and Adaptation of Blood-Stage Malaria Parasites: Challenges for Malaria Elimination.Cold Spring Harbor perspectives in medicine · 2017Review
- The role of the human Duffy antigen receptor for chemokines in malaria susceptibility: current opinions and future treatment prospects.Journal of receptor, ligand and channel research · 2016Article
- Article
- Plasmodium vivax malaria vaccines: why are we where we are?Human vaccines & immunotherapeutics · 2013Review
- Bioinformatics analysis of the structure and function of NADPH-cytochrome p450 reductase ofBiomedical reports · 2013Article
- Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.International journal for parasitology · 2012Review
- Approaching the target: the path towards an effective malaria vaccine.Mediterranean journal of hematology and infectious diseases · 2012Article
- Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.Memorias do Instituto Oswaldo Cruz · 2011Review
- Genetic Diversity in C-terminal of SERA5 Gene in the Blood Stage of Human Isolates ofIranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Plasmodium vivax is the most prevalent malaria parasite on the American continent. It generates a global burden of 80-100 million cases annually and represents a tremendous public health problem, particularly in the American and Asian continents. A malaria vaccine would be considered the most cost-effective measure against this vector-borne disease and it would contribute to a reduction in malaria cases and to eventual eradication. Although significant progress has been achieved in the search for Plasmodium falciparum antigens that could be used in a vaccine, limited progress has been made in the search for P. vivax components that might be eligible for vaccine development. This is primarily due to the lack of in vitro cultures to serve as an antigen source and to inadequate funding. While the most advanced P. falciparum vaccine candidate is currently being tested in Phase III trials in Africa, the most advanced P. vivax candidates have only advanced to Phase I trials. Herein, we describe the overall strategy and progress in P. vivax vaccine research, from antigen discovery to preclinical and clinical development and we discuss the regional potential of Latin America to develop a comprehensive platform for vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.